International Journal of Pharmaceutical Compounding

A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of all issues and individual articles published by the Journal since 1997.

LEARN MORE

The International Academy of Compounding Pharmacists Introduces a New President

Author(s): Rice Baylor

Issue: Mar/Apr 2017 - Volume 21, Number 2
View All Articles in Issue

Page(s): 116-117

The International Academy of Compounding Pharmacists Introduces a New President Page 1

The International Academy of Compounding Pharmacists Introduces a New President Page 2

Download in electronic PDF format for $75

Abstract:

Related Keywords: IACP, U.S. Food and Drug Administration, FDA, pharmacy regulation, Drug Quality and Security Act, DQSA Coalition, office-use compounding, Pharmacy Compouding Advisory Committee, 503A sterile compounding pharmacies, legislators, government advocacy, U.S. Congress, lobbying, Compounders on Capitol Hill

Related Categories: LEGAL, PROFESSIONAL ISSUES

Printer-Friendly Version

Title/Author (Click for Abstract / Details / Purchase)	Issue/Page View/Buy
Related Articles from IJPC
The International Academy of Compounding Pharmacists Introduces a New President Rice Baylor	Mar/Apr 2017 Pg. 116-117
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr	Jul/Aug 2016 Pg. 351 View Sample
Standing Together Fixing the Drug Quality and Security Act Miller David G	Mar/Apr 2015 Pg. 104-106
The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter Miller David G	May/Jun 2014 Pg. 208
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Allen Loyd V Jr	Sep/Oct 2015 Pg. 389-390
PreScription: Drug Quality and Security Act Implementation Subcommittee Hearing Allen Loyd V Jr	Mar/Apr 2018 Pg. 92
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Yoch Doug	Mar/Apr 2017 Pg. 95-102
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr	Nov/Dec 2015 Pg. 487-488
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Allen Loyd V Jr	Sep/Oct 2017 Pg. 356
Legislative/Regulatory Update: From the International Academy of Compounding Pharmacists: Appropriations McCrory Gary	Mar/Apr 2016 Pg. 95-96
Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A Blankenship Cynthia E	Sep/Oct 2014 Pg. 379-380
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Miller David G	Jul/Aug 2015 Pg. 303-305
Applying Quality of Design Concepts to Pharmacy Compounding Timko Robert J	Nov/Dec 2015 Pg. 453-463
U.S. Food and Drug Administration Requests for Input on HR 3204 Enactment: The Drug Quality and Security Act of 2013 Miller David G	Jan/Feb 2014 Pg. 35-36
IACP's Continuing Support of Compounding Pharmacists: Letter to the FDA Concerning 503B Outsourcing Facilities Miller David G	Mar/Apr 2014 Pg. 117-118
The International Academy of Compounding Pharmacists Comments to the Draft Memorandum of Understanding Miller David G	Sep/Oct 2015 Pg. 375
U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)	Nov/Dec 2016 Pg. 457-458
Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA Cabaleiro Joe	Sep/Oct 2021 Pg. 358-362
International Academy of Compounding Pharmacists' Legislative Regulatory Update: Take Action! Stop the U.S. Good and Drug Administration's Misguided Veterminary Guidance Miller David G	Nov/Dec 2015 Pg. 449-450
IACP Legislative/Regulatory Update: The International Academy of Compounding Pharmacists Testifies at U.S. House of Representatives' Energy & Commerce Health Subcommittee Pharmacy Compounding Hearing Blankenship Cynthia	Mar/Apr 2018 Pg. 125-126
Return to Top